1. Medtech Insight
  2. >>Business
  3. >>Deals

9 + 11 = Possible 3: Can A Stryker-Boston Scientific Combo Work?

 
• By Tina Tan

Unconfirmed rumors of Stryker having approached Boston Scientific about a takeover bid raised eyebrows all around, not least because the move – reported on June 11 – was so unexpected. But would a combination of the medtech industry's No. 9 and No. 11, to create a broad-scale portfolio with very little product overlap, make strategic sense? Reactions have been mixed.

Question marks
Rumors of a Stryker/Boston Scientific merger have raised questions about whether a bigger combined company will work

When the rumors about Stryker Corp. making a play for Boston Scientific Corp. first emerged on June 11, the reaction was of unified surprise. The report, by the Wall Street Journal citing sources close to the matter, led to Boston Scientific's share value jumping 17% during intraday trading and Stryker's shares dipping slightly, while market spectators tried to figure out if a possible merger between the industry's No. 9 (Stryker, its ranking in the MTI 100 league table) and No. 11 (Boston Scientific) could actually work.

Based on their respective 2017 full-year revenue, a merger between Stryker and Boston Scientific will result in a company with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 
• By Natasha Barrow

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

More from Business

Somnee AI-Powered Sleep Wearable Raises $10M Seed Round

 
• By Natasha Barrow

The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.

Intuitive Surgical Projects $165M Tariff Hit In 2025, Says Wait-And-See On Mitigation

 
• By Shubham Singh

Despite near-term cost pressures, Intuitive Surgical is expanding manufacturing and R&D in North America and Europe to meet demand for Ion, X and Xi systems.

Three Steps To Investor Heaven For Medtech Founders: Articulate, Explain, Clarify

 
• By Ashley Yeo

Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.